Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Immune escape as a fundamental trait of cancer: focus on IDO.

Prendergast GC.

Oncogene. 2008 Jun 26;27(28):3889-900. doi: 10.1038/onc.2008.35. Review.

PMID:
18317452
2.

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ.

Cancer Immunol Immunother. 2014 Jul;63(7):721-35. doi: 10.1007/s00262-014-1549-4. Review.

3.

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

Katz JB, Muller AJ, Prendergast GC.

Immunol Rev. 2008 Apr;222:206-21. doi: 10.1111/j.1600-065X.2008.00610.x. Review.

PMID:
18364004
4.

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Muller AJ, Prendergast GC.

Curr Cancer Drug Targets. 2007 Feb;7(1):31-40. Review.

PMID:
17305476
5.

Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.

Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R.

Clin Cancer Res. 2011 Nov 15;17(22):6985-91. doi: 10.1158/1078-0432.CCR-11-1331. Review.

6.

Tumor immune escape mediated by indoleamine 2,3-dioxygenase.

Zamanakou M, Germenis AE, Karanikas V.

Immunol Lett. 2007 Aug 15;111(2):69-75. Review.

PMID:
17644189
7.

The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology.

Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM.

Blood. 2009 Mar 12;113(11):2394-401. doi: 10.1182/blood-2008-07-144485. Review.

8.

Marrying immunotherapy with chemotherapy: why say IDO?

Muller AJ, Prendergast GC.

Cancer Res. 2005 Sep 15;65(18):8065-8. Review.

9.

Research progress of indoleamine 2,3-dioxygenase inhibitors.

Jiang T, Sun Y, Yin Z, Feng S, Sun L, Li Z.

Future Med Chem. 2015;7(2):185-201. doi: 10.4155/fmc.14.151. Review.

PMID:
25686005
10.

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

Muller AJ, Malachowski WP, Prendergast GC.

Expert Opin Ther Targets. 2005 Aug;9(4):831-49. Review.

PMID:
16083346
11.

Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway.

Prendergast GC, Metz R, Muller AJ.

Am J Pathol. 2010 May;176(5):2082-7. doi: 10.2353/ajpath.2010.091173. Review.

12.

Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy.

Liu X, Newton RC, Friedman SM, Scherle PA.

Curr Cancer Drug Targets. 2009 Dec;9(8):938-52. Review.

PMID:
20025603
13.

Blocking IDO activity to enhance anti-tumor immunity.

Munn DH.

Front Biosci (Elite Ed). 2012 Jan 1;4:734-45. Review.

PMID:
22201909
14.

Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan.

van Baren N, Van den Eynde BJ.

Cancer Immunol Res. 2015 Sep;3(9):978-85. doi: 10.1158/2326-6066.CIR-15-0095. Review.

15.

The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.

Gostner JM, Becker K, √úberall F, Fuchs D.

Expert Opin Ther Targets. 2015 May;19(5):605-15. doi: 10.1517/14728222.2014.995092. Review.

PMID:
25684107
16.

Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development.

Rutella S, Bonanno G, De Cristofaro R.

Endocr Metab Immune Disord Drug Targets. 2009 Jun;9(2):151-77. Review.

PMID:
19519465
17.

Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Munn DH, Mellor AL.

J Clin Invest. 2007 May;117(5):1147-54. Review.

18.

Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ.

Curr Med Chem. 2011;18(15):2257-62. doi: 0929-8673/11 $58.00+.00. Review.

19.

IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Popov A, Schultze JL.

J Mol Med (Berl). 2008 Feb;86(2):145-60. Review.

PMID:
17876564
20.

Supplemental Content

Support Center